• Reolysin Combo Given to 1st Patient in Phase 1 Trial for Relapsing Myeloma
  • Safety Concerns Lead to Partial Hold of 2 Tecentriq Trials in Myeloma, Lymphoma
  • Sellas’ Cancer Vaccine Galinpepimut-S Shows Durable Effects in High-risk Myeloma Patients
  • Unum’s T-Cell Therapy Enters Phase 1 Trial for Relapsed or Refractory Multiple Myeloma
  • Poseida’s Myeloma-specific CAR T-cells Combat Aggressive Cancer in Mice, Study Shows
  • Myeloma Tests Could Confuse Doctors into Suspecting Relapse, Study Argues
  • Safety Concerns About Other Therapies Prompt FDA to Put a Hold on Three Opdivo Combo Trials
  • FDA Halts Imfinzi Combination Trials After Unexplained Keytruda-related Deaths
  • Long-term Data Confirms Kyprolis Survival Benefit in Relapsed Myeloma Patients
  • Kyprolis Combo Treatment Extends Survival of Relapsed Myeloma Patients, ENDEAVOR Study Shows
  • Darzalex Combos Might Be More Efficient When Used Early in Myeloma
  • Darzalex Combo Therapy Found to Reduce Risk of Myeloma Progression or Death by Half in Newly-diagnosed Patients